Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Cefotetan

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Cefotetan is a 7-α-methoxy β-lactam. A long serum half-life and resistance to β-lactamase hydrolysis have made cefotetan an attractive chemotherapeutic agent, and the results of clinical trials worldwide have demonstrated its efficacy in a wide variety of clinical situations. Cefotetan can be administered intravenously (bolus or infusion) or intramuscularly with lidocaine (lignocaine) 0.5%. Mean peak plasma concentrations are almost linearly related to dose. The volume of distribution is between 8 and 13L and is not different from other cephalosporins. No accumulation is seen after repeated doses and no metabolite has been detected in either plasma or urine. Total body clearance is 1.8 to 2.9 L/h. Renal clearance accounts for about 64 to 84% of a dose, and 75% of a dose is excreted in the urine within 24 hours. The plasma elimination half-life is between 3 and 4 hours after intravenous and intramuscular doses. Half-life is considerably prolonged in patients with renal impairment (up to 10 hours). Cefotetan concentrations are likely to be active against susceptible bacteria in most tissues and body fluids. Breast milk and cerebrospinal fluid concentrations are low. The recommended dosage is 1g every 12 hours, increasing to 2g in severe infections and 3g in life-threatening infections. In surgical prophylaxis, a single dose of 2g is given with the induction of anaesthesia; an additional dose of 2g may be administered 12 hours later. In children over 6 months, the recommended dosage is 30 mg/kg given 12-hourly. In patients with a creatinine clearance of 10 to 40 ml/min (0.6 to 2.4 L/h), the dose is halved or the dosage interval is doubled. When creatinine clearance is less than 10 ml/min (0.6 L/h), the dose is quartered or the dosage interval quadrupled.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adam HK, Houghton HL, Yates RA, Young J, Donnelly RJ. Pharmacokinetics and tolerance of a 24-h infusion of cefotetan disodium (with and without loading dose) in normal Caucasian volunteers. Journal of Antimicrobial Chemotherapy 11 (Suppl. A): 193–199, 1983

    PubMed  CAS  Google Scholar 

  • Andrassy K, Koderisch J. An open study on haemostasis in 20 patients with normal and impaired renal function treated with cefotetan alone or combined with tobramycin. Proceedings of the 15th International Congress of Chemotherapy, Istanbul, 1987

  • Andrassy K, Koderisch J, Bechtold H, Ritz E. Haemostasis during treatment with cefotetan. In Lode et al. (Eds) Cefotetan: a long acting antibiotic for polymicrobial infections, pp. 131–137, Churchill Livingstone, Edinburgh, 1985

    Google Scholar 

  • Aso K, Nakashima T, Miyachi Y, Nishikawa K, Ogawa A, et al. Clinical evaluation of cefotetan in infants and children. In Japanese. Japanese Journal of Antibiotics 36: 131–136, 1983

    Article  Google Scholar 

  • Browning MJ, Holt HA, White LO, Chapman ST, Banks RA, et al. Pharmacokinetics of cefotetan in patients with endstage renal failure on maintenance dialysis. Journal of Antimicrobial Chemotherapy 18: 103–106, 1986

    Article  PubMed  CAS  Google Scholar 

  • Carver PI, Nightingale CH, Quintiliani R. Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers. Journal of Antimicrobial Chemotherapy 23: 99–106, 1989

    Article  PubMed  CAS  Google Scholar 

  • Cho N, Fukunaga K, Kunii K. Fundamental and clinical studies on cefotetan (YM 09330) in the field of obstetrics and gynecology. In Japanese. Chemotherapy (Tokyo) 30: 832–842, 1982

    Google Scholar 

  • Craig WA, Ebert S. Continuous infusion of β-lactam antibiotics. Antimicrobial Agents and Chemotherapy 36: 2577–2583, 1992

    Article  PubMed  CAS  Google Scholar 

  • Craig WA, Leggett J, Totsuka K, Vogelman B. Key pharmacokinetic parameters of antibiotic efficacy in experimental animal infections. Journal of Drug Development 1 (Suppl. 3): 7–15, 1988

    Google Scholar 

  • Daschner FD, Just HM, Petersen EE, Bassler M, Frank U. Penetration of cefotetan into the tissues of female genital tract. In Lode et al. (Eds) Cefotetan: a long acting antibiotic, pp. 110–112, Churchill Livingstone, Edinburgh, 1985

    Google Scholar 

  • Donovan IA, Wise R, Drumm J, Dent J. A comparison of cefotetan and cefazolin in prophylaxis against wound infection after cholecystectomy and the kinetics of cefotetan penetration into peritoneal fluid. Proceedings of the 13th International Congress of Chemotherapy, Vienna, August 28–September 2, SS4.2/9 (Part 25), pp. 57–63, 1983

  • Drumm J, Wise R, Donovan LA. The effect of protein binding on the intraperitoneal penetration of β-lactam antibiotics. British Journal of Surgery 70: 297, 1983

    Google Scholar 

  • Eagle H, Fleischman R, Levy M. “Continuous” versus “discontinuous” therapy with penicillin: the effect of the interval between injections on therapeutic efficacy. New England Journal of Medicine 248: 481–488, 1953

    Article  PubMed  CAS  Google Scholar 

  • Engel K, Schmidt W, Sonntag H-G, Fees K. Comparative clinical and pharmacokinetic aspects of cefotetan versus cefoxitin plus metronidazole in vaginal hysterectomy. Chemioterapia 7: 256–260, 1988

    PubMed  CAS  Google Scholar 

  • Fluckinger U, Segessenmann C, Gerber AU. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted model. Antimicrobial Agents and Chemotherapy 35: 1905–1910, 1991

    Article  Google Scholar 

  • Fraschini F, Gagliardi V. Cefotetan in urinary tract infections: comparison of two dosage schedules. In Lode et al. (Eds) Cefotetan: a long acting antibiotic, pp. 162–166, Churchill Livingstone, Edinburgh 1985

    Google Scholar 

  • Fraschini F, Scaglione F, Mezzetti M, Cicchetti F, Scarpazza P, et al. Pharmacokinetic profile of cefotetan in different clinical conditions. Drugs Under Experimental and Clinical Research 14: 547–553,1988

    PubMed  CAS  Google Scholar 

  • Fujii R, Meguro H, Yoshioka H, Fujita K, Maruyama S, et al. Fundamental and clinical studies on cefotetan in pediatric field. In Japanese. Japanese Journal of Antibiotics 36: 1173–1184, 1983

    PubMed  CAS  Google Scholar 

  • Fujimoto M, Ueda T, Sakai K, Sawada A, Doi S, et al. A clinical trial on cefotetan (YM 09330) in the field of surgery, in Japanese. Chemotherapy (Tokyo) 30: 817–826, 1982

    Google Scholar 

  • Fujimura N, Yuasa M, Yuasa K, Tanaka K, Kurokawa K. Fundamental and clinical studies on cefotetan (YM09330) immunological field. In Japanese. Chemotherapy (Tokyo) 30: 733–740, 1982

    Google Scholar 

  • Furuhata H, Iwai S, Takai K, Sato T, Matsushita K, et al. Cefotetan and cefmetazole concentrations in the tissue of patients at abdominal operations. Proceedings of the 14th International Congress of Chemotherapy. Abstract, p. 194, Kyoto, 1985

  • Gerber A, Feller C, Brugger HP. Time course of the pharmacological response to β-lactam antibiotics in vitro and in vivo. European Journal of Clinical Microbiology 3: 592–597, 1984

    Article  PubMed  CAS  Google Scholar 

  • Gialdroni Grassi G, Alesina R, Ferrara A, Peona V. In vitro antibacterial activity of cefotetan. Journal of Antimicrobial Chemotherapy 11 (Suppl. A): 45–48, 1983

    CAS  Google Scholar 

  • Gruwez JA, Lerut J, Christiaens MR, De Roose J, Vernimmen L, et al. Single-dose prophylaxis with cefotetan in elective abdominal surgery. A controlled trial. Chemioterapia: 218–222, 1988

    Google Scholar 

  • Guibert J, Kitzis MD, Yuelin C, Acar JF. Pharmacokinetics of single intravenous or intramuscular doses of cefotetan in normal human volunteers. Journal of Antimicrobial Chemotherapy 11 (Suppl. A): 201–206, 1983

    PubMed  CAS  Google Scholar 

  • Hirayama A. Clinical study on penetration of cefotetan into CSF. Proceedings of the 14th International Congress of Chemotherapy. Abstract, p. 195, Kyoto, 1985

  • Imaizumi M, Niimi T, Uchida T, Kojita M, Takahashi T, et al. Clinical study on transfer into lung tissue and postoperative prophylactic effect of new cephamycin antibiotics, particularly cefotetan and cefbuperazone. In Japanese. Japanese Journal of Antibiotics 41: 437–459, 1988

    PubMed  CAS  Google Scholar 

  • Inamatsu T, Urayama K, Noro T, Shimada K. Pharmacokinetics and clinical studies of cefotetan in aged patients. Proceedings of the 13th International Congress of Chemotherapy, Vienna, August 28–September 2, SS4.2/9 Part 25, pp. 5–10, 1983

  • Ishino T, Masu C, Hatachi K, Fujii M, Nihira H, et al. Fundamental and clinical studies on cefotetan (YM09330) in the field of urology. In Japanese. Chemotherapy (Tokyo) 30: 719–732, 1982

    Google Scholar 

  • Ishito N, Kumon H, Akazawa N, Miyata K, Okimune M, et al. Pharmacokinetics of antibiotics in patients with impaired renal function. In Japanese. Chemotherapy (Tokyo) 32: 815–822, 1983

    Google Scholar 

  • Iwai N, Sasaki A, Taneda Y, Mizoguchi F, Nakamura H. Fundamental and clinical evaluation of cefotetan in pediatric field. In Japanese. Japanese Journal of Antibiotics 36: 1279–1294, 1983

    Article  PubMed  CAS  Google Scholar 

  • Iwata S, Iwasaki Y, Kanemitsu T, Tojo M, Jozaki K, et al. The basic and clinical studies on cefotetan in the pediatric field. In Japanese. Japanese Journal of Antibiotics 36: 1204–1218, 1983

    PubMed  CAS  Google Scholar 

  • Komatsu T, Nishiya H, Iwata K, Watanabe M, Kunii O. Binding of antibiotics to human liver ligandin. In Periti & Gialdroni Grassi (Eds) Current Chemotherapy and Immunotherapy, vol. 1, pp. 150–151, American Society for Microbiology, Washington, 1981

    Google Scholar 

  • Komiya M, Kikuchi Y, Tachibana A, Yano K. Pharmacokinetics of new broad-spectrum cephamycin, YM09330, parenterally administered to various experimental animals. Antimicrobial Agents and Chemotherapy 20: 176–183, 1981

    Article  PubMed  CAS  Google Scholar 

  • Koyama M, Nakagawa K, Komiya M, Kikuchi Y, Tachibana A, et al. Phase-1 clinical study on cefotetan (YM09330). In Japanese. Chemotherapy (Tokyo) 30: 150–162, 1982

    CAS  Google Scholar 

  • Kuroda Y, Okada H, Harada M, Okada Y, Kamidono J, et al. Clinical application of cefotetan (YM09330) on urinary tract infections. In Japanese. Chemotherapy (Tokyo) 30: 688–702, 1982

    Google Scholar 

  • Lanzini A, Pigozzi G, Facchinetti D, Castellano M, Beschi M, et al. Biliary pharmacokinetic and gallbladder bile concentration of cefotetan in healthy volunteers. Proceedings of the 14th International Congress of Chemotherapy, Abstract, p. 195, Kyoto, 1985

  • Lanzini A, Pigozzi G, Facchinetti D, Wuhrer A, Castellano M, et al. Biliary excretory kinetics of cefotetan in healthy volunteers. Chemioterapia 5 (Suppl. 2): 279–280, 1987

    Google Scholar 

  • Leaper DJ, Cooper MJ, Turner A. A comparative trial between cefotetan and cephazolin for wound sepsis prophylaxis during elective upper gastrointestinal surgery with an investigation of cefotetan penetration into the obstructed biliary tree. Journal of Hospital Infection 7: 269–276, 1986

    Article  PubMed  CAS  Google Scholar 

  • Leggett JE, Fantin B, Ebert S, Totsuka K, Vogelman B, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and high-infection models. Journal of Infectious Diseases 159: 281–292, 1989

    Article  PubMed  CAS  Google Scholar 

  • Martin C, Portet C, Lambert D, Bruguerolle B, Sastre B, et al. Pharmacokinetics and tissue penetration of single-dose cefotetan used for antimicrobial prophylaxis in patients undergoing colorectal surgery. Antimicrobial Agents and Chemotherapy 36: 1115–1118, 1992

    Article  PubMed  CAS  Google Scholar 

  • Matsuda S. Transfer of antibiotics into maternal milk. Biology and Research in Pregnancy 2: 57–60, 1984

    Google Scholar 

  • Matsumoto K. Noguchi Y, Taguchi M, Yoshida T, Yamamoto M, et al. Laboratory and clinical studies on cefotetan (YM09330). In Japanese. Chemotherapy (Tokyo) 30: 595–605, 1982

    Google Scholar 

  • Motomura R, Teramoto C, Souda Y, Fujita A, Chiyoda R, et al. Fundamental and clinical study of cefotetan (YM 09330) in the field of obstetrics and gynecology. In Japanese. Chemotherapy (Tokyo) 30: 882–887, 1982

    Google Scholar 

  • Motta G, Ratto GB, Sacco A, Fraschini F, Scaglione F. Pharmacokinetics of cefotetan: serum, lung and bronchial secretion levels. Proceedings of the 15th International Congress of Chemotherapy, pp. 897–899, Istanbul, 1987

  • Naber K, Kees F, Meyer GP, Grobecker H. In vitro activity, pharmacokinetics safety and therapeutic efficacy of cefotetan in patients with complicated urinary tract infections. Proceedings of the 14th International Congress of Chemotherapy, Abstract, p. 430, Kyoto, 1985a

  • Naber K, Kees F, Meyer GP, Johnson LC, Letzel H, et al. Comparative pharmacokinetic study of cefotetan and cefotaxime in healthy volunteers. In Lode et al. (Eds) Cefotetan: a long acting antibiotic, pp. 88–97, Churchill Livingstone, Edinburgh, 1985b

    Google Scholar 

  • Nagasawa M, Watanabe K, Tanaka H, Cho K, Ito N, et al. Laboratory and clinical studies on cefotetan (YM09330). In Japanese. Chemotherapy (Tokyo) 30: 564–594, 1982

    Google Scholar 

  • Nakagawa K, Koyama M, Tachibana A, Komiya M, Kikuchi Y, et al. Pharmacokinetics of cefotetan (YM09330) in humans. Antimicrobial Agents and Chemotherapy 22: 935–941, 1982

    Article  PubMed  CAS  Google Scholar 

  • Nakayama I, Akieda Y, Kawaguehi H, Ishiyama S. Comparative pharmacokinetic study of cefotetan (YM09330) and latamoxef. In Periti & Gialdroni Grassi (Eds) Current Chemotherapy and Immunotherapy, vol. 1, pp. 433–435, American Society for Microbiology, Washington, 1981

    Google Scholar 

  • Nakayama I, Akieda Y, Tajima K, Kawamura H, Kawaguchi H, et al. Antibacterial activity, absorption, excretion, metabolism, distribution in tissues and clinical use in surgical infections of a new cephamycin antibiotic, cefotetan (YM09330). In Japanese. Chemotherapy (Tokyo) 30: 770–785, 1982

    CAS  Google Scholar 

  • Nishimura T, Takashima T, Hiromatsu K, Tabuki K, Takagi M. Laboratory and clinical studies of cefotetan in the pediatric field. In Japanese. Japanese Journal of Antibiotics 36: 1301–1312, 1983

    PubMed  CAS  Google Scholar 

  • Novelli A, Mazzei T, Ciuffi M, Nicolletti P, Buzzoni P, et al. The penetration of intramuscular cefotetan disodium into human extravascular fluid and maternal milk secretion. Chemioterapia 2: 337–342, 1983

    CAS  Google Scholar 

  • Ohkawa M, Hirano S, Tokunaga S, Motoi I, Shoda R, et al. Pharmacokinetics of cefotetan (YM09330) in healthy volunteers and patients with renal insufficiency. Antimicrobial Agents and Chemotherapy 23: 31–35, 1983

    Article  PubMed  CAS  Google Scholar 

  • Orr JW, Sisson PF, Barrett M, Ellington JR, Jennings RH, et al. Pharmacokinetics and tissue kinetics of 1 gm cefotetan prophylaxis in abdominal or vaginal hysterectomy. American Journal of Obstetrics and Gynecology 158 (Suppl.): 742–743, 1988

    PubMed  Google Scholar 

  • Owen AWM, Manson JMcK, Yates RA, Adshead VM, Houghton HL, et al. The pharmacokinetics of cefotetan excretion in the unobstructed biliary tree. Journal of Antimicrobial Chemotherapy 11 (Suppl. A): 217–221, 1983a

    PubMed  Google Scholar 

  • Owen AWM, Rickards D, Yates RA, Donnelly RJ, Adshead VM, et al. The pharmacokinetics of the excretion of cefotetan into the biliary tree. Proceedings of the 13th International Congress of Chemotherapy, (SP 4.2/9 Part 34, pp. 8–17, 1983b

  • Periti P, Lamanna S, Nicoletti P, Orsi A. Comparative antimicrobial evaluation of cefotetan. Drugs Under Experimental and Clinical Research 9: 267–273, 1983

    CAS  Google Scholar 

  • Quintiliani R, Carver M, Nightingale CH. Comparative pharmacokinetic study of cefotetan and cefoxitin in healthy volunteers. Proceedings of the 14th International Congress of Chemotherapy, pp. 1117, Kyoto, 1985

  • Ripa S, Mignini F, Prenna M. Pharmacokinetics of cefotetan in elderly subjects after intramuscular administration. Chemioterapia 6: 359–363, 1987

    PubMed  CAS  Google Scholar 

  • Saito A, Shimada J, Oomori M, Shiba K, Yamaji T, et al. Clinical studies on cefotetan (YM09330). In Japanese. Chemotherapy (Tokyo) 30: 380–397, 1982a

    Google Scholar 

  • Saito A, Shinohara M, Tomizawa M, Sato K, Kikuchi Y, et al. Studies on cefotetan (YM09330). I. Pharmacokinetics in man. In Japanese. Chemotherapy (Tokyo) 30: 163–173, 1982b

    CAS  Google Scholar 

  • Sawae Y, Okada K, Takemori K, Yokota H. Laboratory and clinical studies on cefotetan (YM09339). In Japanese. Chemotherapy (Tokyo) 30: 551–563, 1982

    Google Scholar 

  • Seiga K, Minagawa M, Egawa J, Noma M, Sugiyama Y. Fundamental and clinical studies on cefotetan (YM 09330). In Japanese. Chemotherapy (Tokyo) 30: 843–868, 1982

    Google Scholar 

  • Serra P, Venditti M, Shinaia M, Microzzi A, Santini C, et al. Cefotetan and amikacin against Gram-negative bacilli: in vitro comparative study with other antibiotics and evaluation of their combined activity. In Lode et al. (Eds) Cefotetan: a long acting antibiotic, pp. 71–73, Churchill Livingstone, Edinburgh 1985

    Google Scholar 

  • Smith BR, LeFrock JL. Cefotetan pharmacokinetics in volunteers with varying degrees of renal function. Drug Intelligence and Clinical Pharmacy 18: 491, 1984

    Google Scholar 

  • Smith BR, LeFrock JL, Thyrum PT, Doret BA, Yeh C, et al. Cefotetan pharmacokinetics in volunteers with various degrees of renal function. Antimicrobial Agents and Chemotherapy 29: 887–893, 1986

    Article  PubMed  CAS  Google Scholar 

  • Soejima R, Matsushima T, Niki Y, Okimoto J, Kawanishi M, et al. Fundamental and clinical studies on cefotetan (YM 09330). In Japanese. Chemotherapy (Tokyo) 30: 524–533, 1982

    CAS  Google Scholar 

  • Stahl JP, Croize J, Bru JP, Gaillat J, Tetelboum R, et al. The pharmacokinetics of cefotetan in the elderly. In Lode et al. (Eds) Cefotetan: a long acting antibiotic, pp. 98–101, Churchill Livingstone, Edinburgh, 1985

    Google Scholar 

  • Suzuki K, Nagakubo I, Mitsui H, Ogawa T, Tamai H, et al. Clinical evaluation of cefotetan (YM09330) on urinary tract infections. In Japanese. Chemotherapy (Tokyo) 30: 653–670, 1982

    Google Scholar 

  • Suzuki K, Naide Y, Okada K, Ohkoshi M, Iki Y. Diffusion into human prostatic fluids of new cephem antibiotic drugs. In Periti & Gialdroni Grassi (Eds) Current Chemotherapy and Immunotherapy, vol. 1, pp. 432–433, American Society for Microbiology, Washington, 1981

    Google Scholar 

  • Tachibana A, Kikuchi Y, Komiya M, Matsui H. Pharmacokinetics and excretion mechanisms of cefotetan in humans. Proceedings of the 14th International Congress of Chemotherapy, Abstract, p. 85, Kyoto, 1985

  • Takase Z, Fujiwara M, Kawamoto Y, Seto M, Shirafuji H, et al. Laboratory and clinical studies of cefotetan (YM09330) in the field of obstetrics and gynaecology. In Japanese. Chemotherapy (Tokyo) 30: 869–881, 1982

    Article  Google Scholar 

  • Tanimura H, Kobayashi N, Sato T, Saito T. Clinical effects of pharmacokinetics of cefotetan in patients with biliary tract infections. Proceedings of the 14th International Congress of Chemotherapy, Abstract, p. 86, Kyoto, 1985

  • Tanimura H, Saito T, Sato T, Sekiya T, Kobayashi N, et al. Chemotherapy of biliary tract infection with special reference to biliary excretion, tissue concentration in gallbladder and clinical effects in patients treated with cefotetan (YM09330). In Japanese. Chemotherapy (Tokyo) 30: 796–815, 1982

    Google Scholar 

  • Toyonaga Y, Kurosu Y, Sugita M, Kita A, Yoshino N, et al. Experimental and clinical evaluation of cefotetan in the field of pediatric infection. In Japanese. Japanese Journal of Antibiotics 36: 1243–1261, 1983

    PubMed  CAS  Google Scholar 

  • Vercruysse J, Hallinck T, Foidart JM, Dombrowicz P, Vanhaecke E, et al. Concentration of cefotetan in female genital tissues: a one-dose study in vaginal and abdominal hysterectomy. Proceedings of the 15th International Congress on Chemotherapy, Istanbul, 1987

  • Welage LS, Borin MT, Wilton JH, Hejmanowski LG, Wels PB, et al. Comparative evaluation of the pharmacokinetics of N-methylthiotetrazole following administration of cefoperazone, cefotetan and cefmetazole. Antimicrobial Agents and Chemotherapy 34: 2369–2374, 1990

    Article  PubMed  CAS  Google Scholar 

  • Wise R, Andrews JM, Hancox J. In vitro activity of cefotetan, a new cephamycin derivative, compared with that of other β-lactam compounds. Antimicrobial Agents and Chemotherapy 21: 486–491, 1982

    Article  PubMed  CAS  Google Scholar 

  • Wise R, Donovan IA, Drumm J, Dent J, Bennett SA. Intraperitoneal penetration of cefotetan. Antimicrobial Agents and Chemotherapy 23: 279–281, 1983

    Article  Google Scholar 

  • Wittke RR, Adam D, Keemss J. Cefotetan in the treatment and prophylaxis of surgical infections: pharmacokinetics in wound secretion, bile and tissues. In Lode et al. (Eds) Cefotetan: a long acting antibiotic, pp 255–262, Churchill Livingstone, Edinburgh, 1985

    Google Scholar 

  • Wright N, Wise R, Hegerty A. Cefotetan elimination in subjects with varying degrees of renal dysfunction. Journal of Antimicrobial Chemotherapy 1 (Suppl. A): 213–216, 1983

    Google Scholar 

  • Yasuda J, Yamamoto T, Itoh M, Honjo H, Okada H, et al. Fundamental and clinical studies on cefotetan in obstetrics and gynaecology. Japanese Journal of Antibiotics 36: 2455–2460, 1983

    PubMed  CAS  Google Scholar 

  • Yates RA, Adam HK, Donnelly RJ, Houghton HL, Charlesworth EA, et al. Pharmacokinetics and tolerance of single intravenous doses of cefotetan disodium in male Caucasian volunteers. Journal of Antimicrobial Chemotherapy 11 (Suppl. A): 185–191, 1983a

    PubMed  CAS  Google Scholar 

  • Yates RA, Cockshott ID, Houghton HL, Wardleworth A, Adam HK, et al. Pharmacokinetics and tolerance of single intramuscular doses of cefotetan in normal Caucasian volunteers. Journal of Antimicrobial Chemotherapy 11 (Suppl. A): 207–212, 1983b

    PubMed  CAS  Google Scholar 

  • Yuk-Choi JH, Nightingale CH, Williams TW. Considerations in dosage selection for third generation cephalosporins. Clinical Pharmacokinetics 22: 132–143, 1992

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anaesthesia Department and Trauma Centre, Hôpital Nord, Marseille, France

    Claude Martin, Laurent Thomachot & Jacques Albanese

Authors
  1. Claude Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurent Thomachot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jacques Albanese
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, C., Thomachot, L. & Albanese, J. Clinical Pharmacokinetics of Cefotetan. Clin. Pharmacokinet. 26, 248–258 (1994). https://doi.org/10.2165/00003088-199426040-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199426040-00002

Keywords

Search

Navigation